Uridine-Based Gadolinium Complex for MRI Contrast
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Gd3+-based MRI contrast agents lack optimal relaxivity profiles at high magnetic fields and do not have sufficient binding affinity for human serum albumin, pH sensitivity, and stability, limiting their effectiveness in providing high-quality tissue contrast and in vivo retention.
Innovation Solution
A uridine-based gadolinium complex with a specific ligand structure, designed to enhance relaxivity, binding affinity with human serum albumin, and pH sensitivity, is developed, which self-assembles into a paramagnetic amphiphile with improved stability and liver specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current Gd3+-based contrast agents are used, then basic MRI imaging is achieved, but relaxivity is insufficient at high magnetic fields
Solution Approach 1:
The patent employs a composite structure combining a DOTA-based gadolinium chelate with a pH-sensitive pyridineazo dye moiety. This composite design allows the contrast agent to exhibit both high relaxivity through the gadolinium complex and pH sensitivity through the azo dye component, resolving the contradiction between achieving sufficient relaxivity and adding functional sensitivity
Solution Approach 2:
The patent modifies the molecular parameters of the contrast agent by introducing a pH-sensitive azo dye group that undergoes structural changes in response to pH variations. This parameter change enables the agent to respond to the acidic microenvironment of tumors while maintaining its gadolinium-based relaxivity mechanism
2Reliability
If conventional gadolinium complexes are used, then basic contrast enhancement is achieved, but binding affinity for human serum albumin is insufficient
Solution Approach 1:
The patent introduces human serum albumin (HSA) as an intermediary carrier for the gadolinium contrast agent. The HSA binding moiety in the contrast agent structure mediates strong non-covalent interaction with serum albumin, thereby extending in vivo circulation time and improving retention without compromising the agent's pH sensitivity or relaxivity
3Adaptability or versatility
If non-pH-responsive contrast agents are used, then simple imaging is achieved, but pH sensitivity for tumor diagnosis is lost
Solution Approach 1:
The patent designs a multi-functional contrast agent that simultaneously provides T1-weighted MRI contrast enhancement, pH sensing capability, and HSA binding functionality. This universal design allows a single molecule to perform multiple diagnostic functions, reducing the need for separate agents while managing structural complexity through modular construction
4Measurement precision
If high relaxivity agents are developed, then image contrast improves, but stability and specificity for particular tissues may be compromised
Solution Approach 1:
The patent applies local quality by creating a contrast agent with differentiated functional regions: a stable DOTA-Gd chelate core for reliable contrast enhancement, a pH-sensitive azo dye region for environmental responsiveness, and an HSA-binding region for targeted retention. Each region performs its specific function while maintaining overall molecular stability and liver specificity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The uridine-based gadolinium complex demonstrates significantly higher relaxivity and stability compared to existing agents, with enhanced binding to human serum albumin and pH responsiveness, making it effective for diagnosing liver abnormalities and providing prolonged in vivo retention and high contrast imaging.
Implementation Method 1
The chelated Gd3+ metal ion improves image contrast by decreasing the longitudinal relaxation time (T1) of proximal water protons
Implementation Method 2
the gadolinium complex into self-assembled nanoparticle system is one of the attractive approaches to develop high relaxivity contrast agent. In this system the high relaxivity achieved due to additive effect of self-aggregated Gd-complexed nuclei and slow global rotational motion
Data Source
AI summary
The present invention relates to a new uridine nucleoside-based amphiphilic gadolinium complex and a magnetic resonance imaging (MRI) contrast agent including the gadolinium complex. The MRI contrast agent has high relaxivity, high binding affinity for and stability in human serum albumin, pH response, and high liver specificity.